Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...
Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...
Biogen (BIIB) stock was granted a Market Perform recommendation by Bernstein ahead of Q4 earnings, citing concerns over its Alzheimer's drug sales. Read more here.
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...
Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.
Zacks.com on MSN17h
Biogen Gears Up to Report Q4 Earnings: What's in the Cards?Biogen BIIB will report fourth-quarter and full-year 2024 results on Feb. 12, before market open. In the last reported ...
DC Magazine on MSN9h
The Ultimate Guide to DC's Philanthropic Events 2025From galas to fashion shows, these are the top charity events coming up this year.Queen Latifah has been a regular at The ...
Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...
thearabianpost on MSN19h
Monoclonal Antibodies: A New Era in Alzheimer’s TreatmentMonoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for ...
The table below is a review of notable updates that occurred in January 2025 for investigational products in development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback